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Original Clinical Science—General
Background. Kidney transplantation confers substantial survival and quality of life benefits for many patients with end-
stage kidney disease compared with dialysis, but complications and side effects of immunosuppression can impair partici-
pation in daily life activities. Life participation is a critically important patient-reported outcome for kidney transplant recipients 
but is infrequently and inconsistently measured in trials. We convened a consensus workshop on establishing an outcome 
measure for life participation for use in all trials in kidney transplantation. Methods. Twenty-five (43%) kidney transplant 
recipients/caregivers and 33 (57%) health professionals from 8 countries participated in 6 facilitated breakout group discus-
sions. Transcripts were analyzed thematically. Results. Four themes were identified. Returning to normality conveyed the 
patients’ goals to fulfill their roles (ie, in their family, work, and community) and reestablish a normal lifestyle after transplant. 
Recognizing the diverse meaning and activities of “life” explicitly acknowledged life participation as a subjective concept that 
could refer to different activities (eg, employment, recreation, family duties) for each individual patient. Capturing vulnerability 
and fluctuations posttransplant (eg, due to complications and side-effects) distinguished between experiences in the first 
year posttransplant and the long-term impact of transplantation. Having a scientifically rigorous, feasible, and meaningful 
measure was expected to enable consistent and frequent assessment of life participation in trials in kidney transplantation. 
Conclusions. A feasible and validated core outcome measure for life participation is needed so that this critically impor-
tant patient-reported outcome can be consistently and meaningfully assessed in trials in kidney transplantation to inform 
decision making and care of recipients.
(Transplantation 2019;103:1199–1205)
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Kidney transplantation is the preferred therapy for many patients with end-stage kidney disease,1 con-
ferring substantial survival and quality of life benefits 
compared with dialysis.2 However, the risk of serious 
comorbidities, including diabetes, cardiovascular disease, 
infection, and cancer, as well as debilitating symptoms 
due to immunosuppression such as cognitive impairment 
and gastrointestinal problems, and the resultant emotional 
distress can limit participation in daily activities.3-5 These 
challenges impair the overall quality of life of kidney trans-
plant recipients.4,6,7 Being able to participate in various 
meaningful activities is a critical outcome for kidney trans-
plant recipients, because they expect to be able to return to 
a healthy life after the transplant.8
Life participation has been established by the 
Standardized Outcomes in Nephrology-Kidney 
Transplantation (SONG-Tx) initiative as a critically 
important core outcome—along with graft health, mor-
tality, cardiovascular disease, infection, and cancer—to 
be reported in all trials in kidney transplant recipients.9 
The core outcomes were identified based on a systematic 
review of outcomes reported in kidney transplantation and 
consensus among more than 1000 kidney transplant recip-
ients, caregivers, and health professionals worldwide.9-11 
In the early phases of the SONG-Tx process, patients pri-
oritized “ability to work” as the most important patient-
reported outcome to report in trials,10 but this had to 
be broadened for the outcome to be directly relevant to 
kidney transplant recipients across all stages of life. Thus, 
“life participation” was included in the core outcome set, 
defined as the ability to participate in activities that pro-
vide a sense of fulfillment, enjoyment, control, and hope. 
This encompassed a range of activities including, but not 
limited to, paid and volunteer work, family duties, social 
functions, recreational and leisure activities, and hobbies.9 
Despite the critical importance of this outcome to patients 
and health professionals, life participation has been incon-
sistently defined and infrequently reported in the context 
of trials.
Studies that have evaluated life participation in kidney 
transplant recipients have used varying terms, such as 
“social participation” and “work ability.”12-14 Life partici-
pation is also embedded within broader constructs, such as 
“health status” and “quality of life.”2,15 Such heterogeneity 
is reflected in the measures used to assess this outcome. 
In a systematic review of 252 studies, 34 different meas-
ures, such as 36-Item Short Form Health Survey (SF-36) 
and EuroQol-5D (EQ-5D), were used to assess “life par-
ticipation.”16 It remains unclear if these measures capture 
“life participation” as conceptualized by kidney transplant 
recipients. Moreover, the comparative effect of interven-
tions across trials is difficult to evaluate, given that these 
measures vary considerably in content (eg, dimensions of 
life participation), length, and psychometric properties.
A standardized measure that assesses life participation in 
a way that is relevant and meaningful to kidney transplant 
recipients that can be used across all trials will facilitate 
comparisons of the effect of interventions on this outcome, 
and ultimately may strengthen the evidence informing 
shared decision making in relation to the critically impor-
tant outcome of life participation. This workshop report 
aims to describe the perspectives of patients, caregivers, 
and health professionals on establishing a core outcome 
measure for life participation to be used in all trials involv-
ing kidney transplant recipients. Although the scope of this 
workshop is to establish a core outcome measure for life 
participation to be used in trials, it may also be relevant in 
other settings, including transplant registries.
CONTEXT AND SCOPE
The SONG-Tx Life Participation consensus workshop 
was convened in Chicago on May 1, 2017, during the 
American Transplant Congress, to enable wider participa-
tion among the transplant community.
ATTENDEES AND CONTRIBUTORS
Of the 58 attendees, 16 (28%) were kidney transplant 
recipients, 9 (15%) were caregivers, and 33 (57%) were 
health professionals including nephrologists, surgeons, 
psychiatrists, psychologists, nurses, researchers, policy 
makers, and industry representatives. Attendees were 
from 8 countries including Australia, Austria, Canada, 
France, Norway, United Kingdom, United States, and 
Vietnam. We invited health professionals with clinical 
experience in kidney transplantation, interest in research 
relating to life participation of kidney transplant recipi-
ents, and/or an advisory or leadership role in relevant 
professional societies (including the American Society of 
Transplantation, The Transplantation Society, Canadian 
Society of Transplantation, Transplantation Society of 
Australia and New Zealand), regulatory and agencies 
(including the Food and Drug Administration and United 
National Organ Sharing), funding organizations (National 
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Institutes of Health), and registries (including the Scientific 
Registry of Transplant Recipients, UK Renal Registry and 
Australian and New Zealand Dialysis and Transplantation 
Registry). Local patients and caregivers were invited by 
United States SONG-Tx Life Participation workshop 
investigators, and received reimbursement for parking and 
ground transportation. All contributors who were unable 
to attend the workshop received a copy of the workshop 
program and draft report to provide feedback. Comments 
and feedback from nonattending contributors were inte-
grated into the final report (Supplemental Materials and 
Methods 1, SDC, http://links.lww.com/TP/B641).
WORKSHOP PROGRAM AND BREAK OUT 
DISCUSSIONS
The workshop program and background materials were 
sent to all attendees and collaborators 2 weeks before the 
workshop. All participants were preassigned to 1 of 6 
break out discussion groups comprising a mix of patients/
caregivers and health professionals to ensure diversity of 
discussion and exchange of expertise. Each group had 9 
to 11 participants, with at least 2 patients and caregivers. 
The breakout discussions commenced after participants 
were informed of the aims and background for the day 
through a short presentation on the SONG-Tx initiative 
and examples of current measures for life participation. 
Each group had a facilitator who moderated the discussion 
using a question guide developed by the SONG-Tx Life 
Participation Expert Working Group and Investigators 
(Supplemental Materials and Methods 2, SDC, http://
links.lww.com/TP/B641).
Participants were asked to discuss the importance of life 
participation as an outcome for trials and provide specific 
input on establishing and implementing a core measure for 
this outcome. To prompt discussion, we provided 3 ques-
tions as proposed measures (EQ-5D Usual Activities - life 
participant subscale,17 and a question each on severity and 
frequency of limitation in life participation), as well as 
examples of frequently used measures including the SF-36 
(daily activities subscale) and the Kidney Disease Quality 
of Life-Short Form (interference of kidney disease in life 
scale). Participants were asked to discuss the 3 examples in 
terms of interpretability, relevance of content, diction, and 
were asked to suggest other measures where appropriate. 
The groups reconvened to provide a brief summary in the 
final plenary session, which was moderated by the work-
shop Chair (M.J.). At the conclusion of the workshop, the 
Chair (M.J.) summarized the key points presented across 
all groups.
The plenary and break out discussions were audio-taped 
and transcribed verbatim. All transcripts were imported 
into HyperRESEARCH software for qualitative data man-
agement. We used thematic analysis to summarize the 
discussion.18 The first author (A.J.) read and conducted 
line-by-line coding of the transcripts to inductively iden-
tify preliminary concepts related to establishing a core 
outcome measure for life participation. The transcripts 
were coded to existing concepts, and new concepts were 
added when necessary. Similar concepts were grouped into 
themes. The coding structure was reviewed independently 
by a second investigator (A.T) and discussed to ensure 
that the themes captured the full range and depth of the 
discussion. All attendees and contributors were invited to 
provide feedback on a draft report containing a descrip-
tion of the themes after the workshop within 2 weeks of 
receipt. Comments and feedback were integrated into the 
final report.
SYNTHESIS OF WORKSHOP DISCUSSION
We identified 4 themes that reflected important aspects 
of life participation that should be included in an outcome 
measure for life participation. Two themes pertained to the 
content (ie, conceptualization of life participation) to be 
captured in the measure: returning to normality and rec-
ognizing the diverse meaning and activities of “life.” The 
2 other themes related to measurement characteristics: 
capturing vulnerability and fluctuations in issues post-
transplant and having a scientifically rigorous, feasible, 
and meaningful measure. Both patients and health profes-
sionals contributed to the themes unless otherwise indi-
cated. The following section describes these themes, and 
quotations to support each theme are presented in Table 1. 
Recommendations that emerged from the consensus work-
shop are listed in Table 2.
Returning to Normality
Adjusting to a New Normal
Some patients accepted that their lives after transplan-
tation were not going to be the same as it was before 
being diagnosed with end-stage kidney disease for various 
reasons including the need to adjust to medication with 
associated side-effects, fear and anxiety of graft loss, and 
restrictions in diet. Rather than feeling limited, there was 
a strong focus on returning to normality but within their 
capabilities as a transplant recipient. One patient men-
tioned that they were “not inhibited, [he] just need[s] to 
adjust.”
Fulfilling One’s Role
Some participants noted that the “activities” of life par-
ticipation could relate to what enabled them to function 
and accomplish important milestones in their lives as well 
as have the ability to resume their “roles.” For example, 
kidney recipients who were parents or the “breadwin-
ners” for their family emphasized that it was important 
for them to be able to “fulfill [their] daily roles in the fam-
ily.” Furthermore, one patient mentioned that as a parent, 
life participation meant being healthy enough to see their 
“kids at a young age grow up to a certain age, send them 
off to college” and other “big achievements.”
Recognizing the Diverse Meaning and Activities of 
“Life”
Differentiating Enjoyment and Participating in 
Activities
Participants explained that being able to enjoy an activ-
ity was different than, but just as important as, being able 
to participate in the activity. Some participants felt that 
survival would be meaningless if they could not enjoy or 
derive satisfaction from the tasks they were able to partici-
pate in. Life participation contributed to overall quality of 
life and patients agreed that they were “more interested in 
quality of life than longevity.”
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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TABLE 1.
Quotations to support each theme
Themes and illustrative quotations
Returning to normality
Adjusting to a new normal
I’m not inhibited, I just have to adjust—P3
That’s part of the challenge, trying to think about how they build their new normal—P3
You start making adjustments to your lifestyle—P4
I think this measure we are talking about here, what is, at different time points after transplant, how much have you achieved by life participation… in 
the view of going back to normal life, active life… measuring against not an unrealistic expectation, but a realistic expectation—P4
I think about [the kidney] all the time, I have stuff on my phone to remind me, time to take meds and stuff like that but I don’t let it restrict anything I 
want to do—P3
Fulfilling one’s role
It’s just different but everybody has responsibilities, [things] to take care of—P3
The important part to me is to have purpose, its, seeing your kids at a young age grow up to a certain age, send them off to college that’s a big 
achievement—P3
how well you carry out your usually social activities and roles—H4
Recognizing the diverse meaning and activities of “life”
Differentiating enjoyment and participation in activities
[patients] might be able to get themselves together to go to a family gathering, but they might have been in the bed all week, things that count as 
opposed to the things that don’t count, that would be the only thing—P1
I’m going housework, I have a moderately hard time doing it but I do it, I push myself to do it, but then again I have a lot of other issues, not being able 
to do stuff… I can’t participate… like going to the mall—P2
See you feel different about going to work, than you do about cutting grass, so I go to work because if they don’t, they don’t like me and they don’t pay 
me anymore, I can let the grass grow—P4
Combination of obligatory and nonobligatory activities
If you said you can only go to work but you can’t travel, it seems kind of, those are, you have to put together, they are both a kind of requirement of 
life—P5
I think what’s mandatory differs from person to person, life stage to life stage, so I think it would be hard to, unless you are going to make a survey 
that’s you know really granular I think it would be hard to determine—P6
In terms of whether one should make mandatory, versus nonmandatory, I’m in favor of not, because for, for my son, he’ll participate in sports, that is 
his life, so now, I’m really, I used to be an athlete, I don’t really care about exercise anymore, it really depends on which stage in your life and so I 
think whatever we develop has to be able to incorporate all those things—C6
[The measure has to be] flexible enough to really show what’s meaningful in a person’s life at that moment—C6
I would lump them together because that’s what life, you have mandatory mixed in with the nonmandatory—P4
Subject to individual interpretation
Everybody has a different purpose and a different way of evaluating what they have achieved—P3
Everybody has a different idea of what they want, and that should be what we are measuring against, not an unrealistic expectation, but a realistic 
expectation, because for some people, it could be sitting on the couch all the time, and [different] for somebody else who may be a professional 
athlete… life participation is that you can participate in what, what percentage of things you want to do, can you achieve, at which time point—H4
Capturing vulnerability and fluctuations in issues posttransplant
Distinguishing first year posttransplant as a critical period of adjustment
I wouldn’t ask patients/recipients to do this during the first year, wait at least a year post transplant—H3
After a year, you sort of know, what you, how it’s affecting your life—P3
We’re a year into it and now it’s just like, now we can go to our actual routine, we don’t have to come here every 2 weeks or something—C3
duration or interval may need to change as a function of how far you are out after transplant so in the initial period, this might be significantly quick 
enough, that you may need to capture 1 week of experience, whereas later down the line, when you’re in a routine, that, more global experience 
over a month would probably capture what, your sort of experiencing—H6
Assessing the long-term impact of transplantation
So we’re basically saying for this is that we think this [recall period of a week] is too limited, these questions, for patient life experience and we think 
maybe just expand it a little bit—H1
A week seems too short there’s too many things that can happen—P1
Because you could just be sick that week or you might have had a doctor appointment that week and that disrupted you going to a meeting maybe at 
work or you had to go to the doctor, I wouldn’t necessarily call that a problem, it’s just something you have to deal with, and maybe you only go once 
a month of once every 6 months, or it could be that week—P3
My first reaction was well if you ask me this at the beginning of May I may have a different answer in August, I mean I look, last week, how narrow is 
that—P4
I would say a month is a time that’s a fair reflection—P6
Continued next page
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
© 2018 Wolters Kluwer Ju et al 1203
Combination of Obligatory and Nonobligatory 
Activities
“Life” was conceptualized as an integration of activities 
required for survival and those that were for enjoyment 
and leisure. Although participants noted the distinction 
between the 2, they believed that disaggregating them 
was unnecessary and difficult because in reality, the com-
bination of all mandatory and nonmandatory activities 
defined “life.” Furthermore, what one patient classifies as 
mandatory may be nonmandatory for others. One patient 
acknowledged that traveling could be classified or per-
ceived as nonmandatory but they considered travel “a 
must, to be able to say that [they] got back to normal life 
participation.” Furthermore, it was considered too granu-
lar and impractical to ask specifically about an individual 
or a group of activities such as working, studying, playing 
sport or traveling for the purpose of assessing life partici-
pation as a core outcome.
Subject to Individual Interpretation
When reading the proposed questions for life partici-
pation (Supplemental Materials and Methods 2, SDC, 
http://links.lww.com/TP/B641), participants interpreted 
the concept of “life participation” and the word “activi-
ties” in their own context. Participation in activities that 
were important for one participant was not necessarily a 
high priority for another. For example, participants may 
have the same ability to participate in activities such as 
work, but some felt this was more important if they had 
to provide for their family, but less critical for those who 
were retired, living alone, and/or on a pension. The val-
ues attached to different activities varied at an individual 
level, and a patient remarked: “in view of going back to 
normal life, active life… everyone has a different idea of 
what they want, and that is what we should be measur-
ing against.”
In addition, using only one specific measurement 
dimension of life participation, such as “how often are 
you limited in your ability to participate in life activities?” 
(frequency) was seen as impractical and less meaningful 
than one that captured a broader dimension such as “I 
have no/slight/moderate/severe problems doing/unable 
to do my usual activities” (EQ-5D).17 The latter was pre-
ferred as it would require patients to incorporate both 
severity and frequency of participation in answering the 
question.
Capturing Vulnerability and Fluctuations in Issues 
Posttransplant
Distinguishing First Year Posttransplant as a Critical 
Period of Adjustment
Both patients and health professionals stated that 
life participation would be more limited in the first 
year posttransplantation than compared with subse-
quent years. They explained that this was because of the 
higher doses of immunosuppression used for induction 
therapy, adjustment to medications, having to attend 
regular appointments, undergo tests, and increased vul-
nerability to possible complications such as infections. 
For example, a patient observed that when they caught 
a cold, they were “sicker…it takes a while to get back 
[recover] because of me immune system.” After the first 
year, patients were seen to be more stable and they “sort 
of know how [the transplant] is affecting [their] life.” 
Thus, participants recommended that the duration or 
the interval of administrating the core outcome measure 
for life participation in a clinical trial should be varied 
to reflect the length of time posttransplant. They sug-
gested that patients within their first year posttransplant 
may need more frequent assessments of life participation 
than in subsequent years after having adjusted to their 
transplant.
TABLE 2.
Summary of workshop recommendations for establishing 
a core outcome measure for life participation
Implications for establishing a core outcome measure for life participation
• The core outcome measure for life participation needs to be applicable 
for all kidney transplant recipients, and should not specify or catego-
rize activities. This will enable patients to interpret life participation in 
their own contexts based on their own individual priorities, goals, and 
values.
• Making a distinction between mandatory and nonmandatory activities is 
unnecessary and impractical because the way in which patients would 
classify specific activities as “necessary” would vary widely. Patients 
want to interpret “life” in their own realm, in reference to what is impor-
tant in their current circumstances.
• A recall time frame that is longer than a week (suggestions range from 
3 wk to 6 mo) is recommended. A week is too short as it is restric-
tive and may not capture the overall experience of the patient, which 
may fluctuate on a weekly basis (particularly during the first year 
posttransplant).
• The time points of administering the outcome measure would depend 
on the duration of time since kidney transplantation. More frequent 
assessments of life participation may be required in the first-year post 
transplant due to the higher risk of complications, adjusting to medica-
tion and the associated emotional distress during this vulnerable period.
Having a scientifically rigorous, feasible and meaningful measure
I think there is a consensus here that whatever it is it needs to be simple—C2
Something that’s validated—H2
Whatever we do, it would have to be validated—H5
I think whatever we develop has to be able to incorporate all those things, and flexible enough to really show what’s meaningful in a person’s life at 
that moment—H6
Simplicity is really critical …make it easier, the simpler the better the question is understood and you get appropriate response with the question—H4
C, caregiver, the number corresponds to the breakout group ID; H, health professional; P, patient.
TABLE 1. (Continued)
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Assessing the Long-term Impact of Transplantation
Overall, participants felt that a recall period of 1 week 
to assess life participation in kidney transplantation is 
“meaningless and too restrictive” as patients can have a 
“bad week” that may bias the results. Suggestions of opti-
mal recall periods ranged from 3 weeks to 6 months.
Having a Scientifically Rigorous, Feasible, and 
Meaningful Measure
Participants believed that an outcome measure would be 
regarded as acceptable, valid and useful if it captured the 
patients’ concept and interpretation of life participation 
after kidney transplantation. The measure had to be “sim-
ple” and produce “measurable and reproducible” data to 
ensure uptake of this measure by the trialists.
DISCUSSION
Life participation is a critically important outcome 
for both kidney transplant recipients and health profes-
sionals who define this concept as “the ability to partici-
pate in activities that give patients a sense of fulfillment, 
enjoyment, control and hope in their lives.” Although the 
outcome refers to a broad range of activities, patients pre-
ferred to interpret this based on their own values, goals, 
and priorities. Differences between mandatory and non-
mandatory activities were noted, but participants agreed 
that the disaggregation of the 2 was unnecessary and dif-
ficult as it may differ according to the individual patient’s 
own interests and circumstances. Therefore, classify-
ing different activities was considered too granular and 
impractical. Similarly, assessing life participation on a sin-
gle measurement dimension, such as severity or frequency 
was also regarded as too specific and a combination of 
both was desired. A longer period of recall (more than 1 
week) was recommended to capture fluctuations in their 
level of life participation, particularly in the first year after 
transplant.
A simple and meaningful measure to assess life partici-
pation in trials involving kidney transplant recipients will 
enable more reliable and valid assessments about the effi-
cacy of interventions in trials. The discussions arising from 
this workshop demonstrate that patients conceptualize life 
participation based on their own context, priorities and 
values, which suggests that measures assessing life partici-
pation need to be framed so as to be sufficiently broad to 
allow individual interpretation. In this way, the outcome 
measure will consistently capture life participation as 
experienced and meaningful to each patient. Attempting 
to narrow down and classify different aspects of “life” 
with terms, such as “social,” “role,” “physical,” and spe-
cific type of activities will not capture life participation as 
experienced by all kidney transplant recipients in various 
stages of life.
Internationally, there is growing interest in using 
patient-reported outcome measures in research to assess 
how a patient feels and functions. Emerging evidence sug-
gests that providing the tool to report symptoms and their 
conditions through monitoring patient-reported outcomes 
may be associated with better outcomes survival.19 The 
US Food and Drug Administration have mandated the 
inclusion of patient reported outcomes to support labe-
ling claims for drugs and devices.20,21 Patient-reported 
outcome measures should be selected based upon what 
is important to patients with the condition being inves-
tigated. Through a consensus process, kidney transplant 
recipients have identified life participation to be a critically 
important outcome.9,10
The discussions and recommendations arising from this 
workshop (provided in Table  2) will directly inform the 
identification of a suitable, existing measure or the develop-
ment of a new core outcome measure that is relevant to the 
kidney transplant recipients. The themes derived from the 
discussion will contribute to the content validity of the out-
come measure. To potentially identify a suitable, existing 
measure, we will consider a wide variety of existing meas-
ures for the outcome measure, including frequently used 
measures, such as the EQ-5D17 and the Patient-Reported 
Outcomes Measurement Information System item bank for 
“ability to participate in social roles and activities.”22 If we 
identify a potentially suitable existing measure based upon 
the recommendations from our workshop, we will pilot this 
through cognitive interviews with kidney transplant recipi-
ents to ascertain comprehension, retrieval, judgment and 
response.23 Before advocating for implementation in clini-
cal trials, the proposed outcome measure will also undergo 
rigorous validation using frameworks established by ini-
tiatives such as Consensus-based Standards for the selec-
tion of health Measurement Instruments-Core Outcome 
Measures in Effectiveness Trials24 and Outcome Measures 
in Rheumatology.25 Psychometric properties such as reli-
ability, responsiveness and content validity can be popula-
tion-specific and may not necessarily be transferrable across 
different populations.26,27 Therefore, validation studies are 
necessary to ensure the measure is appropriate for the pop-
ulation in which it is being used. However, if existing meas-
ures are not sufficient, we will either modify an existing 
measure or develop a new core outcome measure for life 
participation. Once we have preliminary evidence from the 
validation study, we plan to disseminate the core outcome 
measure through research, journals, guidelines, trial net-
works and registries, professional societies, funders, policy/
regulators, and patients/consumers.28
Establishing a valid and relevant outcome measure for 
life participation is expected to improve the consistency 
and reliability in how life participation is assessed and 
reported in trials in kidney transplantation. This will better 
inform decision making and may contribute to the develop-
ment and evaluation of effective interventions to ultimately 
improve life participation in kidney transplant recipients.
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